Search Results

No Results

    Recently Viewed

      Listening...

      Sorry, I don't understand. Please try again
      UK/Our innovation /Focus areas /Oncology /Haematology

      Haematology

      JJ_Illustration_Acute-lymphoblastic-leukaemia_GettyImages_1133641185_1Star.jpg
      Our focus in haematology
      At Johnson & Johnson Innovative Medicine (J&J) we have come a long way in progressing the treatment of people diagnosed with blood cancers over the past 20 years. With more than three decades of history in oncology,1,2,3 our commitment to pioneer new therapeutic advances and continue redefining treatment paradigms in haematology is stronger than ever.

      Our leadership has advanced transformative therapies for haematologic malignancies, and we are committed to continuing to lead in the evolution of our understanding and treatment of these diseases.
        We have demonstrated our UK commitment to haematology during the past year through:
        24
        Medical education meetings
        450
        Consultants attended medical educations meetings
        12
        Clinical publications
        3
        UK grants and donations
        Where we are now
        J&J is focused in areas where patient need is high and our expertise is deep – this includes multiple myeloma and B-cell malignancies, along with other areas of high unmet need within haematology.

        By deepening our understanding of complex forms of blood cancer and taking a patient-focused approach, we’re striving to deliver the next wave of innovations that are tailored to patient’s individual needs and preferences.

        We know that patients need more innovative, personalised therapies that target blood cancers in different ways. Truly personalised medicines and care are tailored to individual disease characteristics which can be key to overcoming treatment resistance. Read more about our work in precision medicine.

        J&J also takes part in collaborative working projects with the NHS to support the delivery of solutions that provide value to patients, healthcare professionals and the health system itself.
        We know the impact blood cancer can have on those affected by the condition, and through continued investment in research and innovation we are steadfast in our commitment to supporting this patient population.”
        Maria Walsh
        Business Unit Director, Haematology, J&J Innovative Medicine, UK.
        JJ_Photo_Scientist-holding-lab-instrument_IM_4Star.jpg
        Our ongoing commitment
        We aim to deliver truly personalised medicines and care for blood cancers, developing therapies that are tailored to individual disease characteristics – something that will be key to overcoming treatment resistance.

        References

        1: Clinicaltrials.gov. Molecular Studies and Clinical Correlations in Human Prostatic Disease. Available at: https://clinicaltrials.gov/ct2/show/NCT00578240. Last accessed September 2024.
        2: ClinicalTrials.gov. Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer Available at: https://clinicaltrials.gov/study/NCT00005648. Last accessed September 2024.
        3: ClinicalTrials.gov. CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy. Available at: https://clinicaltrials.gov/study/NCT00653952?distance=50&term=JOhnson&start=1990-01-01_2000-01-01&rank=4. Last accessed September 2024.

        CP-486601 | November 2024